ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,359,701 | -10.7% | 305,168 | +2.6% | 0.01% | -11.1% |
| Q2 2023 | $7,123,281 | +40.6% | 297,423 | +10.5% | 0.01% | +28.6% |
| Q1 2023 | $5,064,951 | +118.8% | 269,126 | +85.1% | 0.01% | +75.0% |
| Q4 2022 | $2,314,354 | -99.9% | 145,374 | -22.7% | 0.00% | -20.0% |
| Q3 2022 | $3,078,347,000 | +298.8% | 188,163 | +243.4% | 0.01% | +400.0% |
| Q2 2022 | $771,949,000 | -64.2% | 54,787 | -38.4% | 0.00% | -66.7% |
| Q1 2022 | $2,153,618,000 | +30.8% | 88,919 | +26.0% | 0.00% | +50.0% |
| Q4 2021 | $1,646,590,000 | +71.7% | 70,548 | +22.2% | 0.00% | +100.0% |
| Q3 2021 | $958,995,000 | +5.4% | 57,736 | +54.8% | 0.00% | 0.0% |
| Q2 2021 | $909,576,000 | +38.3% | 37,293 | +46.3% | 0.00% | 0.0% |
| Q1 2021 | $657,487,000 | -38.2% | 25,484 | +28.0% | 0.00% | -50.0% |
| Q4 2020 | $1,064,282,000 | +59.7% | 19,908 | +23.2% | 0.00% | +100.0% |
| Q3 2020 | $666,518,000 | -64.7% | 16,158 | -58.6% | 0.00% | -66.7% |
| Q2 2020 | $1,890,282,000 | -39.6% | 38,999 | -47.3% | 0.00% | -50.0% |
| Q1 2020 | $3,128,021,000 | +104.7% | 74,036 | +107.3% | 0.01% | +100.0% |
| Q4 2019 | $1,527,930,000 | -10.0% | 35,716 | -24.3% | 0.00% | 0.0% |
| Q3 2019 | $1,698,116,000 | +45.0% | 47,183 | +7.7% | 0.00% | +50.0% |
| Q2 2019 | $1,170,854,000 | -26.2% | 43,803 | -25.9% | 0.00% | -33.3% |
| Q1 2019 | $1,587,506,000 | +189.3% | 59,125 | +74.2% | 0.00% | +200.0% |
| Q4 2018 | $548,745,000 | -45.3% | 33,936 | -29.7% | 0.00% | 0.0% |
| Q3 2018 | $1,002,687,000 | +61.0% | 48,299 | +18.4% | 0.00% | 0.0% |
| Q2 2018 | $622,955,000 | +4.0% | 40,796 | +53.0% | 0.00% | 0.0% |
| Q1 2018 | $599,005,000 | +6.2% | 26,658 | +42.3% | 0.00% | 0.0% |
| Q4 2017 | $564,021,000 | -36.6% | 18,732 | -20.7% | 0.00% | -50.0% |
| Q3 2017 | $889,991,000 | +51.0% | 23,626 | +11.8% | 0.00% | 0.0% |
| Q2 2017 | $589,511,000 | -10.2% | 21,137 | +10.7% | 0.00% | 0.0% |
| Q1 2017 | $656,624,000 | +1.0% | 19,099 | -15.7% | 0.00% | -33.3% |
| Q4 2016 | $649,851,000 | +3.5% | 22,664 | +14.8% | 0.00% | 0.0% |
| Q3 2016 | $627,929,000 | -6.3% | 19,740 | -4.4% | 0.00% | 0.0% |
| Q2 2016 | $670,429,000 | +37970.9% | 20,654 | +32684.1% | 0.00% | – |
| Q1 2016 | $1,761,000 | -99.7% | 63 | -99.6% | 0.00% | -100.0% |
| Q4 2015 | $584,160,000 | +9.5% | 16,386 | +1.5% | 0.00% | 0.0% |
| Q3 2015 | $533,717,000 | +92.2% | 16,139 | +143.4% | 0.00% | 0.0% |
| Q2 2015 | $277,706,000 | +354.0% | 6,631 | +253.3% | 0.00% | – |
| Q1 2015 | $61,171,000 | -47.9% | 1,877 | -60.4% | 0.00% | – |
| Q3 2014 | $117,362,000 | +1371.8% | 4,740 | +1242.8% | 0.00% | – |
| Q2 2014 | $7,974,000 | +500.0% | 353 | +434.8% | 0.00% | – |
| Q1 2014 | $1,329,000 | -94.2% | 66 | -92.7% | 0.00% | – |
| Q4 2013 | $22,741,000 | -95.7% | 910 | -95.3% | 0.00% | – |
| Q3 2013 | $530,391,000 | +3.3% | 19,308 | -31.8% | 0.00% | – |
| Q2 2013 | $513,627,000 | – | 28,299 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |